EUVIMEDDescubrir EUVIMED
Open access · CC BY 4.0

Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials

Maria Vittoria Chiaruttini iD, Lukas Pin iD, Sofía S Villar iD

Statistics in Medicine · 2026-06 · 45 (13-14)

DOI: 10.1002/sim.70612 ↗

At a glance

Journal article in Statistics in Medicine, published online on 2026-05-26. Written by Maria Vittoria Chiaruttini and 2 co-authors. Institution: Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy. Major MEDLINE topics: Equivalence Trials as Topic, Randomized Controlled Trials as Topic. 35 references. The full text is freely available (open access, CC BY 4.0). Funded by: UK Medical Research Council, MRC Biostatistics Unit Core Studentship, Cusanuswerk e.V.

ResumenSubjectsDatos bibliográficosCiteRelated studies

Abstract (original language)

The majority of response‐adaptive randomization (RAR) designs in the literature rely on efficacy data to guide dynamic patient allocation. However, their applicability becomes limited in settings where efficacy outcomes, such as survival, are observed with a random delay. To address this limitation, we introduce SAFER, a novel RAR design that leverages early‐emerging safety data to inform treatment allocation decisions, particularly in oncology trials. The design is broadly applicable to contexts where prioritizing the arm with superior safety is desirable. This is especially relevant in noninferiority trials, to demonstrate that an experimental treatment is not inferior to the standard of care, while potentially offering improved tolerability. In such trials, an unavoidable trade‐off arises: maintaining statistical efficiency for the efficacy hypothesis while integrating safety‐driven adaptations through RAR. The SAFER design addresses this trade‐off by dynamically adjusting the allocation proportion based on the observed association between safety and efficacy endpoints. We illustrate the performance of SAFER through a simulation study inspired by the CAPP‐IT Phase III oncology trial. Results show that SAFER preserves statistical power, reduces the adverse event rate, and offers flexible adaptation speed depending on the temporal alignment of the endpoints.

Subjects

MeSH terms (MEDLINE)

Equivalence Trials as TopicRandomized Controlled Trials as TopicHumansComputer SimulationNeoplasmsClinical Trials, Phase III as TopicResearch DesignAntineoplastic Agents

Author keywords

FDA Project Optimusadverse eventsefficacyendpoints associationpatient‐benefittoxicity

Substances

Antineoplastic Agents

Authors and institutions

  • Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua, Padua, Italy.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

ORCID profiles: Maria Vittoria Chiaruttini, Lukas Pin, Sofía S Villar

Funding

  • UK Medical Research Council
  • MRC Biostatistics Unit Core Studentship
  • Cusanuswerk e.V
  • PhD scholarship from the University of Padua
  • Medical Research Council

Cite

APA

Vittoria Chiaruttini, M., Pin, L., & Villar, S. S. (2026). Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials. Statistics in Medicine, 45(13-14). https://doi.org/10.1002/sim.70612

Vancouver

Vittoria Chiaruttini M, Pin L, Villar SS. Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials. Statistics in Medicine. 2026;45(13-14). doi:10.1002/sim.70612

BibTeX
@article{VittoriaChiaruttini2026,
  author = {Vittoria Chiaruttini, Maria and Pin, Lukas and Villar, Sofía S},
  title = {Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials},
  journal = {Statistics in Medicine},
  year = {2026},
  volume = {45},
  number = {13-14},
  doi = {10.1002/sim.70612}
}
Start for free →